Ann: US FDA Feedback on Type C Meeting for ATL1102 in the US, page-178

Suwang: You should digest the Anp announcements...before you post .
here’s the thing:
1) Plasma was taken from the Boys D
MD trial and analysed...for other indications about 3 months ago.
2) before the patent could be granted the indication had to have proof of concept ... eg Plasma data ..
3) in the last Webinar Diamond was excited about Neuromuscular and Neurodegenerative diseases.
4 )the webinar in Feb Diamond
definitely stated Alzheimer’s... so Diamond after getting the data from the plasma study must know of its success..
5)I’m thinking outside the box and I think we are one study from Commercialisation $$ in Europe and the US..
for DMD..
6) we will have to do a 9 month Tox study in the US for the other indications....
But who cares in 18 months ... the Anp sp will be over $5